PFBT
SYRE icon

Parkside Financial Bank & Trust’s Spyre Therapeutics SYRE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Buy
45
+10
+29% +$730 ﹤0.01% 1967
2026
Q1 		$1.77K Hold
35
– – ﹤0.01% 2159
2025
Q4 		$1.15K Hold
35
– – ﹤0.01% 2299
2025
Q3 		$587 Hold
35
– – ﹤0.01% 2497
2025
Q2 		$524 Buy
+35
New +$518 ﹤0.01% 2522

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Parkside Financial Bank & Trust's SYRE Position: Q2 2026 in Review

Parkside Financial Bank & Trust increased its Spyre Therapeutics (SYRE) stake by 29% in Q2 2026, buying an estimated $730 and bringing the position to 45 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1967.

Parkside Financial Bank & Trust first reported a position in SYRE in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Parkside Financial Bank & Trust held 45 shares of Spyre Therapeutics worth $4K as of Q2 2026.
  • Parkside Financial Bank & Trust bought 10 Spyre Therapeutics shares in Q2 2026, an estimated $730.
  • Spyre Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1967 holding.
  • Parkside Financial Bank & Trust first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.